The advanced drug formulation technology of CyDex, CAPTISOL^®, is based on a modified cyclodextrin molecule that enables creation of new products by significantly improving the solubility, stability, bioavailablity, safety and dosing of active pharmaceutical ingredients (APIs).

CAPTISOL is one of a series of anionically charged sulfobutyl ether ß-cyclodextrins (SBE-CDs) that were originally synthesized and patented by scientists from the University of Kansas Higuchi Biosciences Center for Drug Delivery Research.

Two Captisol-Enabled^® drugs, Vfend^® I.V. and Zeldox^®/Geodon^® for Injection, have been brought to market in the US and EU by Pfizer Inc., a CyDex corporate partner. Pfizer also recently received approval for Vfend I.V. in Japan. The safety and other characteristics of CAPTISOL have been well profiled and are described in a Drug Master File (DMF) with the U.S. Food and Drug Administration.

CyDex works worldwide with companies interested in licensing CAPTISOL and other SBE-CD technologies. A sample of CAPTISOL is available upon the execution of a confidentiality agreement. Additional supplies can be purchased directly from CyDex. Please contact us via email.